Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Portfolio diversification progressing Hemlibra Ocrevus Evrysdi Phesgo Tecentriq Kadcyla Alecensa Vabysmo Perjeta Xolair Polivy Ronapreve Enspryng Gazyva Gavreto Esbriet Lucentis Actemra/RoActemra Herceptin 30% 17% 106% 241% 11% 14% 19% n/a 5% 11% 91% 132% 8% n/a -14% -17% -10% -16% MabThera -21% Avastin -29% CHFM -800 -400 0 400 Absolute values and growth rates at Constant Exchange Rates (CER) 11% US ■Europe Japan International 800 Roche 20 20

View entire presentation